Reaction
Growth Failure reporting signals
As of the last recalculation, Growth Failure appears in 342 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is ANAKINRA (PRR 120.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Anakinra | 30 | 120.5 | 120.8 |
| Budesonide | 68 | 87.4 | 87.5 |
| Alemtuzumab | 23 | 77.5 | 77.6 |
| Imatinib | 18 | 65.5 | 65.6 |
| Canakinumab | 11 | 63.9 | 64.0 |
| Posaconazole Delayed-Release | 9 | 51.2 | 51.2 |
| Somatropin | 47 | 45.0 | 45.0 |
| Posaconazole | 11 | 42.5 | 42.6 |
| Guanfacine | 5 | 39.2 | 39.3 |
| Melphalan | 14 | 39.0 | 39.0 |
| Fludarabine Phosphate | 22 | 36.3 | 36.3 |
| Baricitinib | 5 | 32.0 | 32.0 |
| Palivizumab | 4 | 16.0 | 16.0 |